Frazier Life Sciences Management L.P. Decreases Stake in Vaxcyte, Inc. $PCVX

by · The Markets Daily

Frazier Life Sciences Management L.P. decreased its position in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 12.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 474,405 shares of the company’s stock after selling 65,000 shares during the quarter. Frazier Life Sciences Management L.P.’s holdings in Vaxcyte were worth $15,423,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of PCVX. Eventide Asset Management LLC raised its stake in Vaxcyte by 80.4% in the second quarter. Eventide Asset Management LLC now owns 848,141 shares of the company’s stock valued at $27,573,000 after buying an additional 377,911 shares during the last quarter. Engineers Gate Manager LP grew its position in Vaxcyte by 66.3% during the 2nd quarter. Engineers Gate Manager LP now owns 160,808 shares of the company’s stock worth $5,228,000 after purchasing an additional 64,111 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Vaxcyte by 175.9% in the second quarter. BNP Paribas Financial Markets now owns 139,124 shares of the company’s stock worth $4,523,000 after buying an additional 88,692 shares during the last quarter. Boothbay Fund Management LLC lifted its stake in shares of Vaxcyte by 58.5% during the second quarter. Boothbay Fund Management LLC now owns 103,267 shares of the company’s stock worth $3,357,000 after buying an additional 38,109 shares during the period. Finally, Brevan Howard Capital Management LP acquired a new position in shares of Vaxcyte in the 2nd quarter valued at $1,788,000. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Trading Down 0.2%

Shares of PCVX stock opened at $44.50 on Friday. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $93.77. The stock has a market cap of $5.83 billion, a P/E ratio of -9.19 and a beta of 1.28. The stock has a 50 day moving average of $44.83 and a 200 day moving average of $37.47.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period last year, the business earned ($0.83) EPS. On average, research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on PCVX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday, October 14th. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, September 12th. They set a “neutral” rating and a $38.00 target price for the company. Leerink Partners set a $77.00 price target on shares of Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Finally, BTIG Research restated a “buy” rating and set a $85.00 price objective on shares of Vaxcyte in a research note on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.83.

Get Our Latest Stock Report on Vaxcyte

Vaxcyte Company Profile

(Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Featured Articles

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX – Free Report).